Omalizumab (Xolair) in patients with steroid-resistant asthma: Lessons to be learnt

Philip Thompson; Neil Misso; John Woods

doi:10.1111/j.1440-1843.2007.01017.x

Omalizumab (Xolair) in patients with steroid-resistant asthma: Lessons to be learnt

Philip Thompson, Neil Misso, John Woods

School of Population and Global Health

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.

Original language	English
Pages (from-to)	29-34
Journal	Respirology
Volume	12
Issue number	Supp. 3
DOIs	https://doi.org/10.1111/j.1440-1843.2007.01017.x
Publication status	Published - 2007

Access to Document

10.1111/j.1440-1843.2007.01017.x

Cite this

@article{7dcbd9b1f3684e43bcadf7e86d432cda,

title = "Omalizumab (Xolair) in patients with steroid-resistant asthma: Lessons to be learnt",

abstract = "Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.",

author = "Philip Thompson and Neil Misso and John Woods",

year = "2007",

doi = "10.1111/j.1440-1843.2007.01017.x",

language = "English",

volume = "12",

pages = "29--34",

journal = "Respirology",

issn = "1323-7799",

publisher = "John Wiley & Sons",

number = "Supp. 3",

}

TY - JOUR

T1 - Omalizumab (Xolair) in patients with steroid-resistant asthma: Lessons to be learnt

AU - Thompson, Philip

AU - Misso, Neil

AU - Woods, John

PY - 2007

Y1 - 2007

N2 - Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.

AB - Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.

U2 - 10.1111/j.1440-1843.2007.01017.x

DO - 10.1111/j.1440-1843.2007.01017.x

M3 - Article

VL - 12

SP - 29

EP - 34

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - Supp. 3

ER -

Omalizumab (Xolair) in patients with steroid-resistant asthma: Lessons to be learnt

Abstract

Access to Document

Fingerprint

Cite this